THMO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
THMO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ThermoGenesis Holdings's average Accounts Receivable for the three months ended in Dec. 2023 was $0.66 Mil. ThermoGenesis Holdings's Revenue for the three months ended in Dec. 2023 was $2.41 Mil. Hence, ThermoGenesis Holdings's Days Sales Outstanding for the three months ended in Dec. 2023 was 24.97.
The historical rank and industry rank for ThermoGenesis Holdings's Days Sales Outstanding or its related term are showing as below:
During the past 13 years, ThermoGenesis Holdings's highest Days Sales Outstanding was 127.01. The lowest was 37.96. And the median was 68.41.
ThermoGenesis Holdings's Days Sales Outstanding declined from Dec. 2022 (66.85) to Dec. 2023 (24.97).
The historical data trend for ThermoGenesis Holdings's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ThermoGenesis Holdings Annual Data | |||||||||||||||||||||
Trend | Jun14 | Jun15 | Jun16 | Jun17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Days Sales Outstanding | Get a 7-Day Free Trial | 38.98 | 49.82 | 41.53 | 45.23 | 54.37 |
ThermoGenesis Holdings Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Days Sales Outstanding | Get a 7-Day Free Trial | 66.85 | 50.02 | 34.71 | 23.75 | 24.97 |
For the Medical Devices subindustry, ThermoGenesis Holdings's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, ThermoGenesis Holdings's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where ThermoGenesis Holdings's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Accounts Receivable can be measured by Days Sales Outstanding.
ThermoGenesis Holdings's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as
Days Sales Outstanding (A: Dec. 2023 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Dec. 2022 ) | + | Accounts Receivable (A: Dec. 2023 )) | / | count ) | / | Revenue (A: Dec. 2023 ) | * | Days in Period |
= | ( (1.865 | + | 0.949) | / | 2 ) | / | 9.445 | * | 365 |
= | 1.407 | / | 9.445 | * | 365 | ||||
= | 54.37 |
ThermoGenesis Holdings's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:
Days Sales Outstanding (Q: Dec. 2023 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Sep. 2023 ) | + | Accounts Receivable (A: Dec. 2023 )) | / | count ) | / | Revenue (A: Dec. 2023 ) | * | Days in Period |
= | ( (0.368 | + | 0.949) | / | 2 ) | / | 2.406 | * | 365 / 4 |
= | 0.6585 | / | 2.406 | * | 365 / 4 | ||||
= | 24.97 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ThermoGenesis Holdings (NAS:THMO) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Thank you for viewing the detailed overview of ThermoGenesis Holdings's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.
Xiaochun Xu | director | 2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616 |
Biao Xi | director | C/O THERMOGENESIS HOLDINGS, INC., 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742 |
James Xu | director | 2453 S. ARCHER AVE, SUITE B, CHICAGO IL 60616 |
Haihong Zhu | director | 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742 |
Debra Donaghy | director | C/O THERMOGENESIS HOLDINGS, INC., 2711 CITRUS RD., RANCHO CORDOVA CA 95742 |
Boyalife (hong Kong) Ltd | 10 percent owner | 2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616 |
Thomis Joseph | director | MALEIZENSTRAAT 66, HERENT C9 B-3020 |
Boyalife Asset Holding Ii, Inc. | 10 percent owner | 2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616 |
Boyalife Group, Inc. | 10 percent owner | 2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616 |
Russell M Medford | director | 7935 FAWNDALE WAY, ATLANTA GA 30350 |
Mark Westgate | director | 350 CORPORATE BOULEVARD, ROBBINSVILLE NJ 08691 |
Jeffery Cauble | officer: Principal Accounting Officer | 2711 CITRUS CT., RANCHO CORDOVA CA 95742 |
Vivian H Liu | director | |
Boyalife Investment Inc. | 10 percent owner | 2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616 |
Mark Bagnall | director | 3876 BAY CENTER PLACE, HAYWARD CA 94545 |
From GuruFocus
By PRNewswire PRNewswire • 05-19-2022
By PRNewswire PRNewswire • 07-07-2022
By PRNewswire PRNewswire • 05-15-2023
By PRNewswire PRNewswire • 06-08-2022
By PRNewswire • 08-10-2023
By PRNewswire PRNewswire • 05-28-2022
By PRNewswire PRNewswire • 12-21-2022
By PRNewswire PRNewswire • 11-07-2022
By PRNewswire PRNewswire • 06-07-2022
By PRNewswire • 07-17-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.